List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF) - Overview
Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF) - Companies Involved in Therapeutics Development
Asklepios BioPharmaceutical Inc
Biogen Inc
Copernicus Therapeutics Inc
Eli Lilly and Co
Kai Nuo Bio Sci Co Ltd
Kolon Life Science Inc
Lauren Sciences LLC
Neuroptika Inc
Sinfonia Biotherapeutics Inc
Stem Cell Medicine Ltd
Treeway BV
UniQure NV
Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF) - Drug Profiles
AMT-090 - Drug Profile
Product Description
Mechanism Of Action
History of Events
Drugs for Neurodegenerative Diseases - Drug Profile
Product Description
Mechanism Of Action
EpiRepair - Drug Profile
Product Description
Mechanism Of Action
Fusion Protein to Activate GDNF for Brain Ischemia - Drug Profile
Product Description
Mechanism Of Action
Gene Therapy to Activate GDNF for Amyotrophic Lateral Sclerosis and Retinitis Pigmentosa - Drug Profile
Product Description
Mechanism Of Action
History of Events
Gene Therapy to Activate GDNF for Multiple System Atrophy and Parkinson's Disease - Drug Profile
Product Description
Mechanism Of Action
History of Events
Gene Therapy to Activate GDNF for Parkinson's Disease - Drug Profile
Product Description
Mechanism Of Action
KLS-2031 - Drug Profile
Product Description
Mechanism Of Action
History of Events
LAUR-101 - Drug Profile
Product Description
Mechanism Of Action
LAUR-301 - Drug Profile
Product Description
Mechanism Of Action
NRO-1 - Drug Profile
Product Description
Mechanism Of Action
History of Events
Protein to Activate GDNF for Parkinson's Disease - Drug Profile
Product Description
Mechanism Of Action
ST-502 - Drug Profile
Product Description
Mechanism Of Action
History of Events
Stem Cell Therapy to Activate BDNF, GDNF, IGF1 and VEGF for Peripheral Nerve Injury and Neuropathic Pain - Drug Profile
Product Description
Mechanism Of Action
History of Events
TW-002 - Drug Profile
Product Description
Mechanism Of Action
History of Events
Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF) - Dormant Products
Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF) - Product Development Milestones
Featured News & Press Releases
Jun 18, 2021: CIRM Board approves new clinical trial for ALS
Aug 17, 2020: Neuroptika completes enrollment in phase 2 clinical trial for Dry Eye Disease
Apr 27, 2020: Kolon Life Sciences launches follow-up pipeline to administer the first patient in the US
Jan 17, 2020: Neuroptika enrols first patient for dry eye disease trial
Apr 30, 2019: Neuroptika announces positive data from NRO-1 phase 1 clinical trial
Mar 11, 2019: Kolon gets FDA nod for testing gene therapy for neuropathic pain
Dec 26, 2018: Neuroptika, Spun Out from Senju Pharmaceutical launches to develop novel regenerative treatment
Dec 26, 2018: Neuroptika, spun out from Senju Pharmaceutical launches to develop novel regenerative treatment
Oct 20, 2016: Cedars-Sinai Receives Approval to Test Novel Combined Stem Cell and Gene Therapy for ALS Patients
Apr 19, 2016: Lauren Sciences awarded second grant for LAUR-301 from The ALS Association
Dec 13, 2010: Sangamo Announces Publication Of Data From Program To Develop ZFP Therapeutic For Parkinson's Disease In Journal Of Neuroscience.
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development by Stage of Development, 2022
Number of Products under Development by Therapy Areas, 2022
Number of Products under Development by Indication, 2022
Number of Products under Development by Companies, 2022
Products under Development by Companies, 2022
Number of Products under Investigation by Universities/Institutes, 2022
Products under Investigation by Universities/Institutes, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Pipeline by Asklepios BioPharmaceutical Inc, 2022
Pipeline by Biogen Inc, 2022
Pipeline by Copernicus Therapeutics Inc, 2022
Pipeline by Eli Lilly and Co, 2022
Pipeline by Kai Nuo Bio Sci Co Ltd, 2022
Pipeline by Kolon Life Science Inc, 2022
Pipeline by Lauren Sciences LLC, 2022
Pipeline by Neuroptika Inc, 2022
Pipeline by Sinfonia Biotherapeutics Inc, 2022
Pipeline by Stem Cell Medicine Ltd, 2022
Pipeline by Treeway BV, 2022
Pipeline by UniQure NV, 2022
Dormant Projects, 2022

List of Figures
Number of Products under Development by Stage of Development, 2022
Number of Products under Development by Therapy Areas, 2022
Number of Products under Development by Top 10 Indications, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Routes of Administration, 2022
Number of Products by Stage and Routes of Administration, 2022
Number of Products by Molecule Types, 2022
Number of Products by Stage and Molecule Types, 2022

Companies Mentioned
• Asklepios BioPharmaceutical Inc
• Biogen Inc
• Copernicus Therapeutics Inc
• Eli Lilly and Co
• Kai Nuo Bio Sci Co Ltd
• Kolon Life Science Inc
• Lauren Sciences LLC
• Neuroptika Inc
• Sinfonia Biotherapeutics Inc
• Stem Cell Medicine Ltd
• Treeway BV
• UniQure NV